IMMUNO PHOTONICS

PIONEERING INTERVENTIONAL IMMUNO-ONCOLOGY™

Developing a Novel Immune Stimulant to Activate the Body's Natural Defense against Solid Tumor Cancers

2023

IMMUNO PHOTONICS



EXECUTIVE SUMMARY

Immunophotonics is a privately owned biotech developing a novel therapy to treat solid tumor cancers. Utilized after routine procedures that destroy cancer inside the body such as tumor ablation or radiation, IP-001, the first asset from broad intellectual property, captures tumor-identifying material and uses it to create an immune response against the cancer. IP-001 transforms treatments that treat single tumors into a cancer immunotherapy able to find, attack, and optimally eliminate the cancer throughout the body.
The main aspects of the therapy are:

- ✓ **Generates immune response specific to the patient's cancer:** IP-001 delivers a tumor specific immune response from an off-the-shelf-drug.
- ✓ **Tumor type agnostic:** Applicable to a variety of solid tumor cancers.
- ✓ **No complicated processes:** Integrates seamlessly into a routine treatment as a simple injection directly into the tumor.
- ✓ **Major market opportunity:** Applicable to hundreds of thousands of thermal ablations and potentially millions of radiation or chemotherapy treatments. Can improve outcomes of these standard of care treatments.
- ✓ **Excellent drug safety:** Patients often feel well and can go home the same day as treatment. Typical side effects are similar to those of a vaccination.

POTENTIAL IMPACT OF IP-001:

- ✓ **Improved control of treated tumor:** reduction or elimination of residual tumor cells and reduction of recurrence.
- ✓ **Induced attack of distant tumors (metastases):** The activated immune response is systemic and seeks out cancer targets throughout the body.
- ✓ **Long-lasting immune response:** Research to-date shows that the induced immune system surveillance and memory response can prevent cancer recurrence.
- ✓ **Enhanced efficacy of other cancer treatments:** The multimodal nature of the IP-001-mediated immune response generated from the whole repertoire of tumor antigens available can enhance the success of other treatments that require immune activation, such as checkpoint inhibition.
- ✓ **Multi-billion USD de novo market opportunity** in the first indications in clinical development. Intellectual property granted on composition of matter patent in 51 countries with follow-on patents pending.



Industry: Therapeutics, Oncology

Stage: Clinical phase 2a, safety & tolerability confirmed in phase 1b with positive signals of immune response, early translational data validates nonclinical mechanisms

Current Indications: Solid tumors, advanced melanoma, soft tissue sarcoma, colorectal and non-small cell lung cancer

Clinical Trial Locations: Switzerland, UK, France, Germany, US (IND submitted)

HIGHLIGHTED TEAM MEMBERS

Lu Alleruzzo: CEO, co-founder

Edwina Baskin-Bay, MD: CMO, immuno-oncology expert, former Janssen and Astellas senior executive

Samuel Lam, PhD: Senior VP of Science & Research, immunology expert

Tomas Hode, PhD: President, Chief Innovation Officer, co-founder

David Anderson, PhD: CSO, serial entrepreneur, drug development expert, former CSO Celgene and Ignyta

Theresa Visarius, PhD: VP Bus. Dev., pharma & innovation expert

HIGHLIGHTED BOARD MEMBERS

Bobby W. Sandage, Jr., PhD: Board Chairman, prior public biotech CEO, Euclises Pharma. CEO

Charlie Bolten, PhD: BioGenerator, Investor

Miguel Zubizarreta Entrepreneur & Investor

Jonathan Knowles, PhD: Prior Genentech & Chugai Board, prior Roche Global Head of Research

Wei R. Chen, PhD: Immunophotonics co-founder, multi-million $ grant recipient for study of IP-001

HIGHLIGHTED ADVISORS

Markus Joerger, MD, PhD: Clinical Trial Principal Investigator, President Developmental Therapeutics, SAKK

Rob Martin MD, PhD: Clinical Advisor, Head of Surgical Oncology, University of Louisville

Daniel Von Hoff MD, PhD: Clinical Advisor, US Oncology CSO, TGen Director of Translational Research

Richard A. Stark: Tumor ablation & medical device expert

immunophotonics.com | IR@immunophotonics.com | US: +1 (314) 675-0159 | CH: +41 79 343 4593

Abscopalize it ™

Immunophotonics has discovered a unique way of activating the immune system to combat cancer. This approach has the potential to improve the way many cancers are treated and is anticipated to have profound impact on patient outcomes.

Our innovation completes routine interventional procedures with an injection of the Immunophotonics superadjuvant, IP-001, into the tumor.

This *abscopalizes* the treatment, which means that treating just a single tumor can generate a specific immune response against the cancer that effects the whole body.

This new approach brings added clinical value to routine interventional procedures conducted everyday that are effective in killing the treated tumor, yet do not address the underlying problem of the systemic nature of cancer.

Immunophotonics' vision is to *abscopalize* routine procedures for single tumors with an innovation that treats the disease, not just the tumor.

Reach out to us if you would like to know more.

IMMUNO PHOTONICS

GENERAL INQUIRIES:
info@immunophotonics.com

INVESTMENT OPPORTUNITIES AND PARTNERING:
IR@immunophotonics.com

HEADQUARTERS
Immunophotonics, Inc.
4340 Duncan Ave.
BioGenerator Labs, Suite 212
St. Louis MO, 63110

SWISS OFFICE
IPS Biopharma AG
a subsidiary of Immunophotonics, Inc.
sitem-insel
Freiburgstrasse 3
3010 Bern, Switzerland